234 related articles for article (PubMed ID: 34775332)
1. Medicinal chemistry updates of novel HDACs inhibitors (2020 to present).
He X; Hui Z; Xu L; Bai R; Gao Y; Wang Z; Xie T; Ye XY
Eur J Med Chem; 2022 Jan; 227():113946. PubMed ID: 34775332
[TBL] [Abstract][Full Text] [Related]
2. An update on the emerging approaches for histone deacetylase (HDAC) inhibitor drug discovery and future perspectives.
Su M; Gong X; Liu F
Expert Opin Drug Discov; 2021 Jul; 16(7):745-761. PubMed ID: 33530771
[TBL] [Abstract][Full Text] [Related]
3. Chemical Versatility in Catalysis and Inhibition of the Class IIb Histone Deacetylases.
Christianson DW
Acc Chem Res; 2024 Apr; 57(8):1135-1148. PubMed ID: 38530703
[TBL] [Abstract][Full Text] [Related]
4. Structure, mechanism, and inhibition of histone deacetylases and related metalloenzymes.
Lombardi PM; Cole KE; Dowling DP; Christianson DW
Curr Opin Struct Biol; 2011 Dec; 21(6):735-43. PubMed ID: 21872466
[TBL] [Abstract][Full Text] [Related]
5. The effect of various zinc binding groups on inhibition of histone deacetylases 1-11.
Madsen AS; Kristensen HM; Lanz G; Olsen CA
ChemMedChem; 2014 Mar; 9(3):614-26. PubMed ID: 24375963
[TBL] [Abstract][Full Text] [Related]
6. Activity-Guided Design of HDAC11-Specific Inhibitors.
Son SI; Cao J; Zhu CL; Miller SP; Lin H
ACS Chem Biol; 2019 Jul; 14(7):1393-1397. PubMed ID: 31264832
[TBL] [Abstract][Full Text] [Related]
7. Structure-Based Inhibitor Discovery of Class I Histone Deacetylases (HDACs).
Luo Y; Li H
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33266366
[TBL] [Abstract][Full Text] [Related]
8. Technologies of targeting histone deacetylase in drug discovery: Current progress and emerging prospects.
Ru J; Wang Y; Li Z; Wang J; Ren C; Zhang J
Eur J Med Chem; 2023 Dec; 261():115800. PubMed ID: 37708798
[TBL] [Abstract][Full Text] [Related]
9. Phenylpyrrole-based HDAC inhibitors: synthesis, molecular modeling and biological studies.
Brindisi M; Cavella C; Brogi S; Nebbioso A; Senger J; Maramai S; Ciotta A; Iside C; Butini S; Lamponi S; Novellino E; Altucci L; Jung M; Campiani G; Gemma S
Future Med Chem; 2016 Sep; 8(13):1573-87. PubMed ID: 27556815
[TBL] [Abstract][Full Text] [Related]
10. Discovery of novel class of histone deacetylase inhibitors as potential anticancer agents.
El-Awady R; Saleh E; Hamoudi R; Ramadan WS; Mazitschek R; Nael MA; Elokely KM; Abou-Gharbia M; Childers WE; Srinivasulu V; Aloum L; Menon V; Al-Tel TH
Bioorg Med Chem; 2021 Jul; 42():116251. PubMed ID: 34116381
[TBL] [Abstract][Full Text] [Related]
11. Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.
Wang Y; Wallach J; Duane S; Wang Y; Wu J; Wang J; Adejare A; Ma H
Drug Des Devel Ther; 2017; 11():1369-1382. PubMed ID: 28496307
[TBL] [Abstract][Full Text] [Related]
12. The Development Process: from SAHA to Hydroxamate HDAC Inhibitors with Branched CAP Region and Linear Linker.
Yang F; Zhao N; Hu Y; Jiang CS; Zhang H
Chem Biodivers; 2020 Jan; 17(1):e1900427. PubMed ID: 31793143
[TBL] [Abstract][Full Text] [Related]
13. An update on lysine deacylases targeting the expanding "acylome".
Olsen CA
ChemMedChem; 2014 Mar; 9(3):434-7. PubMed ID: 24375937
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylases: structural determinants of inhibitor selectivity.
Micelli C; Rastelli G
Drug Discov Today; 2015 Jun; 20(6):718-35. PubMed ID: 25687212
[TBL] [Abstract][Full Text] [Related]
15. Targeting histone deacetylases for heart diseases.
Jin G; Wang K; Zhao Y; Yuan S; He Z; Zhang J
Bioorg Chem; 2023 Sep; 138():106601. PubMed ID: 37224740
[TBL] [Abstract][Full Text] [Related]
16. Discussion on structure classification and regulation function of histone deacetylase and their inhibitor.
Han H; Feng X; He T; Wu Y; He T; Yue Z; Zhou W
Chem Biol Drug Des; 2024 Jan; 103(1):e14366. PubMed ID: 37776270
[TBL] [Abstract][Full Text] [Related]
17. Strategies in developing promising histone deacetylase inhibitors.
Zhang L; Fang H; Xu W
Med Res Rev; 2010 Jul; 30(4):585-602. PubMed ID: 19634125
[TBL] [Abstract][Full Text] [Related]
18. Inhibitory selectivity among class I HDACs has a major impact on inflammatory gene expression in macrophages.
Cao F; Zwinderman MRH; van Merkerk R; Ettema PE; Quax WJ; Dekker FJ
Eur J Med Chem; 2019 Sep; 177():457-466. PubMed ID: 31181405
[TBL] [Abstract][Full Text] [Related]
19. Inside HDACs with more selective HDAC inhibitors.
Roche J; Bertrand P
Eur J Med Chem; 2016 Oct; 121():451-483. PubMed ID: 27318122
[TBL] [Abstract][Full Text] [Related]
20. Dual inhibitors of histone deacetylases and other cancer-related targets: A pharmacological perspective.
Gao Y; Zhang H; Lirussi F; Garrido C; Ye XY; Xie T
Biochem Pharmacol; 2020 Dec; 182():114224. PubMed ID: 32956642
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]